Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Marinus Pharma CS
(NQ:
MRNS
)
1.480
-0.030 (-1.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Marinus Pharma CS
< Previous
1
2
3
4
5
Next >
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings
October 11, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)
September 22, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 09, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
September 07, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million
August 29, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 12, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 11, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder
July 28, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 15, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
July 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022
July 13, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
June 08, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 03, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
May 18, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 12, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 10, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
May 05, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
April 20, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
April 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
March 31, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 21, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
March 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 15, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
February 22, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
February 16, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 10, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
February 03, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.